# CagriSema FDA approval · PepVault guides

Source: https://pepvault.app/guides/cagrisema-fda-decision

Last updated: 2026-11-20

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Guides](https://pepvault.app/guides) [GLP-1s](https://pepvault.app/guides#glp1)

# CagriSema FDA approval: when it's due, the dose filed, and what the trials showed

Reviewed November 2026 17 sources [Published by PepVault](https://pepvault.app/guides/how-we-research)

CagriSema is not FDA approved yet (Nov 20, 2026); Novo expects a decision in Q4 2026. The dose it filed, the warnings to expect and five trials' numbers.

- **Last reviewed:** Nov 20, 2026
- **Sources:** 17
- **Questions:** 7
- **Compounds:** 3

## The short answer

Not yet. As of November 20, 2026, the FDA has not approved CagriSema, Novo Nordisk's weekly shot of cagrilintide 2.4 mg plus semaglutide 2.4 mg. Novo filed it on December 18, 2025, and expects a US decision in the fourth quarter of 2026 and a launch in early 2027. In its main trial, weight fell 20.4% at 68 weeks, against 3.0% on placebo.

Every number checked at its primary source · Nov 20, 2026 · [17 sources](https://pepvault.app/guides/cagrisema-fda-decision#sources) · [How we research](https://pepvault.app/guides/how-we-research)

**Evidence:** Strong for weight loss: five randomized phase 3 trials (REDEFINE 1, 2, 4, 5 and 9), two of them in the New England Journal of Medicine, all funded by Novo Nordisk. The approval itself is pending: decision and launch dates are Novo's expectations, not FDA statements.

## Is CagriSema FDA approved yet?

No. On November 20, 2026, the FDA's drug database lists no approved product containing cagrilintide[13](https://pepvault.app/guides/cagrisema-fda-decision#source-13), and neither the FDA nor Novo Nordisk has announced a decision. This page is updated the day one is.

What is on the table: Novo submitted a new drug application (NDA, the file a company sends the FDA to ask for approval) on December 18, 2025 for once-weekly cagrilintide 2.4 mg and semaglutide 2.4 mg, for adults with obesity, or overweight with at least one weight-related condition, beside a reduced-calorie diet and more activity[1](https://pepvault.app/guides/cagrisema-fda-decision#source-1). The file rests on REDEFINE 1 and REDEFINE 2[1](https://pepvault.app/guides/cagrisema-fda-decision#source-1). In its nine-month report on November 4, 2026, Novo said it is "preparing for the US launch of CagriSema in early 2027, subject to regulatory approval"[2](https://pepvault.app/guides/cagrisema-fda-decision#source-2), and its milestone table puts the US decision in the fourth quarter of 2026[2](https://pepvault.app/guides/cagrisema-fda-decision#source-2) [3](https://pepvault.app/guides/cagrisema-fda-decision#source-3).

Why it matters: it would be the first approved shot to pair GLP-1 with amylin. Cagrilintide is an amylin analogue, a long-acting copy of the fullness hormone the pancreas releases with insulin, and semaglutide is the GLP-1 drug in Wegovy and Ozempic. The two curb appetite through partly different routes in the brain, and in REDEFINE 1 the pair lost more weight than either drug alone[5](https://pepvault.app/guides/cagrisema-fda-decision#source-5).

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Once CagriSema is prescribed, PepVault can remind you on your shot day, log each weekly dose as you took it, and keep your weight beside it, so each step-up is easy to review with your prescriber.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## When will the FDA decide on CagriSema?

Novo's word is the fourth quarter of 2026[2](https://pepvault.app/guides/cagrisema-fda-decision#source-2) [3](https://pepvault.app/guides/cagrisema-fda-decision#source-3). Neither Novo nor the FDA has published the exact goal date, so the date below is our arithmetic from the FDA's own rules, not an announcement.

Cagrilintide has never been approved, so we expect the FDA to review CagriSema as a new molecular entity. Under the FDA's user-fee goals, a standard review of a new molecular entity aims to end with a decision within 10 months of the 60-day filing date, about 12 months after the file arrives[12](https://pepvault.app/guides/cagrisema-fda-decision#source-12). For a December 18, 2025 submission, the filing date is February 16, 2026, and ten months on is about December 16, 2026. If Novo sends a major amendment during the review, such as a big new analysis, the FDA may push the date back by three months, once per review[12](https://pepvault.app/guides/cagrisema-fda-decision#source-12). The decision can be an approval or a complete response letter, the FDA's list of what must be fixed first.

| Date | What happened or is expected | Whose date |
| --- | --- | --- |
| Dec 20, 2024 | REDEFINE 1 headline results[5](https://pepvault.app/guides/cagrisema-fda-decision#source-5) | Fixed (Novo announcement) |
| Jun 22, 2025 | REDEFINE 1 and 2 published in NEJM[6](https://pepvault.app/guides/cagrisema-fda-decision#source-6) [7](https://pepvault.app/guides/cagrisema-fda-decision#source-7) | Fixed |
| Dec 18, 2025 | NDA submitted to the FDA[1](https://pepvault.app/guides/cagrisema-fda-decision#source-1) | Fixed (Novo announcement) |
| Feb 23, 2026 | REDEFINE 4 head to head with tirzepatide reported[4](https://pepvault.app/guides/cagrisema-fda-decision#source-4) | Fixed (Novo announcement) |
| Nov 14, 2026 | REDEFINE 9, the lower doses, published[9](https://pepvault.app/guides/cagrisema-fda-decision#source-9) | Fixed |
| Q4 2026 | US decision[2](https://pepvault.app/guides/cagrisema-fda-decision#source-2) [3](https://pepvault.app/guides/cagrisema-fda-decision#source-3) | Novo's expectation |
| Early 2027 | US launch, if approved[2](https://pepvault.app/guides/cagrisema-fda-decision#source-2) | Novo's expectation |
| Mar 1, 2027 | REDEFINE 11 primary completion[10](https://pepvault.app/guides/cagrisema-fda-decision#source-10) | Registry estimate, ClinicalTrials.gov |

## What dose did Novo file, and what dose steps did the trials use?

The application names one maintenance dose: 2.4 mg of cagrilintide plus 2.4 mg of semaglutide, once a week[1](https://pepvault.app/guides/cagrisema-fda-decision#source-1). CagriSema doses are written per drug, so 2.4 mg/2.4 mg means 2.4 mg of each. No label exists yet, so the steps below are the trials', not an approved schedule.

| Trial step | Dose of each drug | Source |
| --- | --- | --- |
| Start | 0.25 mg once a week | REDEFINE 9[9](https://pepvault.app/guides/cagrisema-fda-decision#source-9) |
| Step-ups | Every 4 weeks | REDEFINE 11 record[10](https://pepvault.app/guides/cagrisema-fda-decision#source-10) |
| After 8 weeks | 1.0 mg reached (the lowest maintenance dose tested) | REDEFINE 9[9](https://pepvault.app/guides/cagrisema-fda-decision#source-9) |
| After 12 weeks | 1.7 mg reached | REDEFINE 9[9](https://pepvault.app/guides/cagrisema-fda-decision#source-9) |
| After 16 weeks | 2.4 mg reached, the filed maintenance dose | REDEFINE 1 record[11](https://pepvault.app/guides/cagrisema-fda-decision#source-11) |

REDEFINE 1 let people adjust their dose along the way. At week 68, 57.3% of people on CagriSema were on the top dose, against 70.2% on semaglutide alone and 82.5% on cagrilintide alone[5](https://pepvault.app/guides/cagrisema-fda-decision#source-5). Novo followed with two trials: REDEFINE 9, which tested lower maintenance doses, and REDEFINE 11, which tests 2.4 mg/2.4 mg in people who aim to lose a quarter of their weight.

REDEFINE 9 is the newest result. Counting people as if they stayed on treatment, weight fell 21.0% on 1.0 mg of each and 20.7% on 1.7 mg of each, against 2.0% on placebo[9](https://pepvault.app/guides/cagrisema-fda-decision#source-9). Whether a first label includes those lower doses is one of the things to read on decision day: the application as announced named 2.4 mg/2.4 mg[1](https://pepvault.app/guides/cagrisema-fda-decision#source-1). Which dose a person takes, and when they step up, is the prescriber's decision.

<!--promo-->

Once CagriSema is prescribed, PepVault can remind you on your shot day, log each weekly dose as you took it, and keep your weight beside it, so each step-up is easy to review with your prescriber. [Set reminders in PepVault](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-cagrisema-fda-decision-inline&mt=8)

<!--/promo-->

## With this guide

### CagriSema

- [CagriSema: the full reference](https://pepvault.app/peptides/cagrisema)
- [CagriSema dose guide](https://pepvault.app/lab/dosage/cagrisema)

### Cagrilintide

- [Cagrilintide: the full reference](https://pepvault.app/peptides/cagrilintide)
- [Cagrilintide dose guide](https://pepvault.app/lab/dosage/cagrilintide)

### Mixing charts

- [Cagrilintide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/cagrilintide-5mg)
- [Cagrilintide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/cagrilintide-10mg)
- [Semaglutide 2 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-2mg)
- [Semaglutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-5mg)
- [Semaglutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-10mg)

### Studies

- [CagriSema: 30.3% hit both BMI and waist-to-height targets at 68 weeks](https://pepvault.app/research/cagrilintide-redefine-1-2026)
- [CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5](https://pepvault.app/research/cagrisema-redefine-5-2026)
- [CagriSema: HbA1c down 2.33% at 40 weeks in REIMAGINE 3](https://pepvault.app/research/cagrisema-reimagine-3-2026)
- [All 4 studies](https://pepvault.app/research#cagrisema)
- [All 7 studies](https://pepvault.app/research#cagrilintide)

### Compared with

- [CagriSema vs Semaglutide](https://pepvault.app/peptides/compare/cagrisema-vs-semaglutide)
- [CagriSema vs Tirzepatide](https://pepvault.app/peptides/compare/cagrisema-vs-tirzepatide)
- [CagriSema vs Amycretin](https://pepvault.app/peptides/compare/cagrisema-vs-amycretin)
- [Cagrilintide vs Semaglutide](https://pepvault.app/peptides/compare/cagrilintide-vs-semaglutide)
- [Retatrutide vs Cagrilintide](https://pepvault.app/peptides/compare/retatrutide-vs-cagrilintide)
- [Tirzepatide vs Cagrilintide](https://pepvault.app/peptides/compare/tirzepatide-vs-cagrilintide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)

### The GLP-1 path

- [Retatrutide week by week](https://pepvault.app/guides/retatrutide-week-by-week)
- [Retatrutide dosage: the trial step-ups](https://pepvault.app/guides/retatrutide-dosage-in-trials)
- [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)
- [Semaglutide week by week](https://pepvault.app/guides/semaglutide-week-by-week)
- [Tirzepatide dosage: every step from 2.5 to 15 mg (Mounjaro and Zepbound)](https://pepvault.app/guides/tirzepatide-dosage)
- [Wegovy and Ozempic dosage: both labels' steps in one table, and why the two differ](https://pepvault.app/guides/wegovy-and-ozempic-dosage)
- [How to use the Zepbound KwikPen](https://pepvault.app/guides/how-to-use-the-zepbound-kwikpen)
- [How to use the Ozempic and Wegovy pens: needles, the dose counter and clicks](https://pepvault.app/guides/how-to-use-ozempic-and-wegovy-pens)
- [What time of day to take your GLP-1 shot or pill, and can you change the day?](https://pepvault.app/guides/when-to-take-your-glp-1)
- [Switching GLP-1s: Ozempic to Zepbound, shot to pill, and what the trials tested](https://pepvault.app/guides/switching-between-glp-1s)
- [Ozempic vs Wegovy vs Mounjaro vs Zepbound: the four labels in one table](https://pepvault.app/guides/ozempic-wegovy-mounjaro-zepbound)
- [Is Ozempic insulin? GLP-1, GIP and insulin explained](https://pepvault.app/guides/is-ozempic-insulin)
- [The Wegovy pill: what it is, how its label differs from the shot, and the trial numbers](https://pepvault.app/guides/the-wegovy-pill)
- [Ozempic and Wegovy side effects: what the trials counted and when they showed up](https://pepvault.app/guides/ozempic-and-wegovy-side-effects)
- [Semaglutide vs tirzepatide side effects: what the head-to-head trials found](https://pepvault.app/guides/sema-vs-tirzepatide-side-effects)
- [Microdosing a GLP-1: what it means and what has been tested](https://pepvault.app/guides/microdosing-a-glp-1)
- [GLP-1s and sleep apnea: Zepbound's OSA approval](https://pepvault.app/guides/glp-1-and-sleep-apnea)
- [Retatrutide first dose: the first four weeks in the trials](https://pepvault.app/guides/retatrutide-first-dose)
- [Retatrutide side effects: what the trials counted](https://pepvault.app/guides/retatrutide-side-effects)
- [Retatrutide not working? Stalls, slow responders and the plateau](https://pepvault.app/guides/retatrutide-not-working)
- [Switching from tirzepatide to retatrutide: what is known](https://pepvault.app/guides/tirzepatide-to-retatrutide)
- [Is retatrutide safe? What the trials reported](https://pepvault.app/guides/is-retatrutide-safe)
- [When will retatrutide be approved?](https://pepvault.app/guides/when-will-retatrutide-be-approved)
- [TRIUMPH-5 results: retatrutide vs tirzepatide head to head](https://pepvault.app/guides/triumph-5-results)
- [MariTide phase 3 results (MARITIME-1): what to expect](https://pepvault.app/guides/maritime-1-results)
- [Aleniglipron: the GLP-1 pill, and the trial switching people from shots to it](https://pepvault.app/guides/aleniglipron-switch-trial)
- [Mounjaro and Zepbound side effects by dose: the rates at each step](https://pepvault.app/guides/mounjaro-zepbound-side-effects)
- [Hair loss on a GLP-1: how common it is per drug, and why](https://pepvault.app/guides/hair-loss-on-a-glp-1)
- ["Ozempic face": what it is, and where the weight comes from](https://pepvault.app/guides/ozempic-face)
- [Foundayo (orforglipron) vs the shots: the trial numbers side by side](https://pepvault.app/guides/foundayo-vs-the-shots)
- [Is compounded semaglutide or tirzepatide the same as Ozempic or Zepbound?](https://pepvault.app/guides/compounded-glp-1-vs-brand)
- [Why compounded semaglutide and tirzepatide come with B12, glycine or B6, and what it changes](https://pepvault.app/guides/compounded-glp-1-with-b12)
- [Is there a generic Ozempic? Generic semaglutide and Sevmia](https://pepvault.app/guides/generic-semaglutide)
- [How much does a GLP-1 cost in 2026? Zepbound, Wegovy and Medicare prices](https://pepvault.app/guides/how-much-does-a-glp-1-cost)
- [What to eat on a GLP-1: what the trials and the guidelines say](https://pepvault.app/guides/what-to-eat-on-a-glp-1)
- [How much protein per day? The numbers by weight and goal](https://pepvault.app/guides/how-much-protein-per-day)
- [Muscle on a GLP-1: how much of the weight lost is lean mass?](https://pepvault.app/guides/muscle-on-a-glp-1)
- [Intermittent fasting on a GLP-1: what the trials and labels say](https://pepvault.app/guides/intermittent-fasting-on-a-glp-1)
- [Coffee on a GLP-1: can you drink it, and why it can taste different](https://pepvault.app/guides/coffee-on-a-glp-1)
- [Food noise on a GLP-1: what it is and what happens after stopping](https://pepvault.app/guides/food-noise-on-a-glp-1)
- [GLP-1s and menopause: what the trials say about women in midlife](https://pepvault.app/guides/glp-1s-and-menopause)
- [Stopping a GLP-1: what happens to your weight](https://pepvault.app/guides/stopping-a-glp-1)
- [How to keep the weight off after a GLP-1: what each trial tested](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1)
- [Berberine vs metformin vs a GLP-1: what each does to weight and glucose](https://pepvault.app/guides/berberine-vs-metformin-vs-glp-1)
- [Natural GLP-1 alternatives: what the evidence shows for berberine, fiber and supplements](https://pepvault.app/guides/natural-glp-1-alternatives)
- [What is 5-Amino-1MQ? What's been measured](https://pepvault.app/guides/5-amino-1mq-explained)
- [Retatrutide from a lab vial: what independent testing found](https://pepvault.app/guides/retatrutide-lab-vial-tests)
- [Switching from Saxenda to Wegovy: how the change works](https://pepvault.app/guides/saxenda-to-wegovy)
- [Do you stop Ozempic, Wegovy, Mounjaro or Zepbound before surgery?](https://pepvault.app/guides/glp-1-before-surgery)
- [Diarrhea on a GLP-1: how common, and how long it lasts](https://pepvault.app/guides/diarrhea-on-a-glp-1)
- [Dizziness on a GLP-1: dehydration, blood pressure or blood sugar?](https://pepvault.app/guides/dizziness-on-a-glp-1)
- [Heartburn and acid reflux on a GLP-1: the rates, the timing and what helps](https://pepvault.app/guides/heartburn-on-a-glp-1)
- [Does Ozempic or Mounjaro make you tired? Fatigue in the trials](https://pepvault.app/guides/glp-1-fatigue)
- [Can a GLP-1 cause low blood sugar if you do not have diabetes?](https://pepvault.app/guides/glp-1-low-blood-sugar)
- [Is there a medicine for GLP-1 nausea? Tradipitant, so far](https://pepvault.app/guides/tradipitant-for-glp-1-nausea)
- [GLP-1s and mood: depression, anxiety and what the FDA review found](https://pepvault.app/guides/glp-1s-and-mood)
- [Can Ozempic cause vision loss? GLP-1s and NAION, by the numbers](https://pepvault.app/guides/glp-1-and-naion)
- [Are GLP-1s safe long term? What the longest trials show](https://pepvault.app/guides/are-glp-1s-safe-long-term)
- [GLP-1s and the kidneys: what FLOW showed, and the dehydration risk](https://pepvault.app/guides/glp-1s-and-the-kidneys)
- [Can you drink alcohol on Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/alcohol-on-a-glp-1)
- [Do GLP-1s reduce alcohol cravings? What the trials found](https://pepvault.app/guides/glp-1-and-alcohol-cravings)
- [GLP-1s and fatty liver: what the trials measured](https://pepvault.app/guides/glp-1-and-fatty-liver)
- [GLP-1s after a gastric sleeve or bypass: regain, dosing and sleeve vs GLP-1](https://pepvault.app/guides/glp-1-after-bariatric-surgery)
- [Can you drink alcohol on retatrutide?](https://pepvault.app/guides/retatrutide-and-alcohol)
- [Ozempic, Wegovy, Mounjaro or Zepbound not working? Slow responders and plateaus in the trials](https://pepvault.app/guides/glp-1-not-working)
- [Intermittent fasting for weight and fat loss: what the trials measured](https://pepvault.app/guides/intermittent-fasting-weight-loss)
- [Can you take metformin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/metformin-with-a-glp-1)
- [GLP-1s and pregnancy: Ozempic, Wegovy, Mounjaro and Zepbound before and during](https://pepvault.app/guides/glp-1s-and-pregnancy)
- [Can you take Ozempic, Mounjaro or another GLP-1 while breastfeeding?](https://pepvault.app/guides/glp-1-while-breastfeeding)
- [Eloralintide, petrelintide and amycretin: the amylin drugs in trials](https://pepvault.app/guides/amylin-drugs-in-trials)
- [Olatorepatide (HS-20094): Regeneron's obesity drug, what is known so far](https://pepvault.app/guides/olatorepatide-explained)
- [Cagrilintide and CagriSema: what amylin adds to semaglutide](https://pepvault.app/guides/cagrilintide-and-cagrisema)
- [Berobenatide (PF-08653944, MET-097i): Pfizer's monthly GLP-1 shot, what is known so far](https://pepvault.app/guides/berobenatide-explained)
- [The GLP-1 pipeline: every drug in phase 2 and 3, and when its trials finish](https://pepvault.app/guides/glp-1-pipeline)
- [Is there a monthly GLP-1 shot? MariTide and berobenatide](https://pepvault.app/guides/monthly-glp-1-shots)
- [Cagrilintide alone: RENEW 1 phase 3 results and what to expect](https://pepvault.app/guides/renew-1-cagrilintide-results)
- [Wegovy HD: is 7.2 mg worth it, and what changes from 2.4 mg](https://pepvault.app/guides/wegovy-hd-7-2-mg)
- [Zenagamtide (amycretin): Novo's GLP-1 and amylin shot and pill, what the trials show](https://pepvault.app/guides/zenagamtide-amycretin)
- [Wegovy and Ozempic price, Medicare and WADA: what changes on January 1, 2027](https://pepvault.app/guides/glp-1-changes-january-2027)
- [Can you take sermorelin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/sermorelin-with-a-glp-1)
- [Retatrutide in women: what the studies included](https://pepvault.app/guides/retatrutide-in-women)
- [Peptides for women: what the trials in women show, and after 40](https://pepvault.app/guides/peptides-for-women)
- [Low-dose naltrexone (LDN) for weight loss: what the trials measured](https://pepvault.app/guides/ldn-for-weight-loss)
- [GLP-1s and PCOS: what the trials show, and how they compare with metformin](https://pepvault.app/guides/glp-1-and-pcos)
- [GLP-1s and sleep: insomnia, vivid dreams and the sleep apnea approval](https://pepvault.app/guides/glp-1s-and-sleep)

### Terms on this page

- [Maintenance dose](https://pepvault.app/glossary/maintenance-dose)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [Placebo](https://pepvault.app/glossary/placebo)
- [FDA approval](https://pepvault.app/glossary/fda-approval)
- [New drug application (NDA)](https://pepvault.app/glossary/nda)
- [Boxed warning](https://pepvault.app/glossary/boxed-warning)
- [Primary endpoint](https://pepvault.app/glossary/primary-endpoint)
- [Amylin analogue](https://pepvault.app/glossary/amylin-analogue)

## What did the CagriSema trials show?

Five phase 3 obesity trials have reported, all funded by Novo. Two ways of counting appear below. The treatment-policy number counts everyone who started, including those who stopped the drug; the efficacy number estimates what happens if everyone stays on treatment, and runs higher.

| Trial | Who and how long | Weight change | Stopped for side effects |
| --- | --- | --- | --- |
| REDEFINE 1[5](https://pepvault.app/guides/cagrisema-fda-decision#source-5) [6](https://pepvault.app/guides/cagrisema-fda-decision#source-6) | 3,417 adults without diabetes, 68 weeks | −20.4% vs −3.0% placebo, semaglutide alone −14.9%, cagrilintide alone −11.5% (treatment policy); −22.7% vs −2.3% placebo (efficacy) | 5.9% vs 3.5% on placebo[1](https://pepvault.app/guides/cagrisema-fda-decision#source-1) |
| REDEFINE 2[7](https://pepvault.app/guides/cagrisema-fda-decision#source-7) | 1,206 adults with type 2 diabetes, 68 weeks | −13.7% vs −3.4% placebo (treatment policy) | 8.4% vs 3% on placebo[1](https://pepvault.app/guides/cagrisema-fda-decision#source-1) |
| REDEFINE 5[8](https://pepvault.app/guides/cagrisema-fda-decision#source-8) | 331 adults in Japan and Taiwan, with or without type 2 diabetes, 68 weeks | −18.4% vs −11.9% on semaglutide 2.4 mg (efficacy) | 10% stopped CagriSema, 6% semaglutide (any reason) |
| REDEFINE 9[9](https://pepvault.app/guides/cagrisema-fda-decision#source-9) | 309 adults without diabetes, 68 weeks, lower doses | −21.0% (1.0 mg each), −20.7% (1.7 mg each) vs −2.0% placebo (efficacy) | Not in the abstract; 82% still on treatment at week 68 |
| REDEFINE 4[4](https://pepvault.app/guides/cagrisema-fda-decision#source-4) [17](https://pepvault.app/guides/cagrisema-fda-decision#source-17) | 809 adults with obesity, 84 weeks, open label, vs tirzepatide 15 mg | −23.0% vs −25.5% (efficacy); −20.2% vs −23.6% (treatment regimen) | Not reported in the announcement |

Two results frame the decision. Against placebo and against semaglutide alone, CagriSema won clearly: in REDEFINE 1, 40.4% of people lost a quarter or more of their body weight if they stayed on treatment, against 16.2% on semaglutide alone[5](https://pepvault.app/guides/cagrisema-fda-decision#source-5). Against tirzepatide 15 mg, the Zepbound top dose, it did not reach its goal of proving it no worse[4](https://pepvault.app/guides/cagrisema-fda-decision#source-4). The application rests on the placebo-controlled REDEFINE 1 and 2[1](https://pepvault.app/guides/cagrisema-fda-decision#source-1), so a missed head-to-head goal does not by itself decide the review. How CagriSema, Zepbound and Wegovy compare is its own guide.

## What side effects and warnings will the label likely carry?

Mostly stomach and gut effects, like every GLP-1 drug. In REDEFINE 1, 79.6% on CagriSema had a gut side effect at some point, against 39.9% on placebo, mostly passing and mild to moderate[6](https://pepvault.app/guides/cagrisema-fda-decision#source-6): nausea in 55%, constipation in 30.7% and vomiting in 26.1%[1](https://pepvault.app/guides/cagrisema-fda-decision#source-1). In REDEFINE 2 the gut rate was 72.5% against 34.4%[7](https://pepvault.app/guides/cagrisema-fda-decision#source-7), and in REDEFINE 5, against semaglutide alone, it was 53% against 51%[8](https://pepvault.app/guides/cagrisema-fda-decision#source-8).

The label's exact wording is the FDA's to write. CagriSema contains semaglutide, so Wegovy's label is the closest guide. It has a boxed warning, the FDA's strongest, because semaglutide caused thyroid C-cell tumors in rodents; whether it does in people is unknown, and the drug is ruled out for anyone with a personal or family history of medullary thyroid cancer or MEN 2[14](https://pepvault.app/guides/cagrisema-fda-decision#source-14). Its other warnings cover pancreatitis, gallbladder disease, low blood sugar with insulin or a sulfonylurea, kidney injury from dehydration, severe stomach effects, allergic reactions, diabetic eye complications, a faster heart rate, and the risk of inhaling stomach contents under anesthesia[14](https://pepvault.app/guides/cagrisema-fda-decision#source-14). Our expectation is that a CagriSema label opens with the same boxed warning; whether amylin adds anything new is what the label will show.

**Commonly reported:** strong appetite loss and fullness arriving early in a meal, with nausea, vomiting or constipation in the days after each step-up, settling once the dose holds steady.

**When to get help** Severe stomach pain that does not ease, sometimes reaching the back, is the semaglutide label's sign to stop and call a doctor[14](https://pepvault.app/guides/cagrisema-fda-decision#source-14).

## What is REDEFINE 11, and when does it report?

REDEFINE 11 is Novo's answer to the dose question REDEFINE 1 left open: the trial "exploring CagriSema 2.4/2.4 mg full weight-loss potential", expected to report in the first half of 2027[4](https://pepvault.app/guides/cagrisema-fda-decision#source-4) [2](https://pepvault.app/guides/cagrisema-fda-decision#source-2). The registry record that matches Novo's description, NCT07011667, enrolled 609 adults with a BMI of 30 or more and no diabetes at 47 US sites, every one of whom said they wished to lose at least 25% of their weight[10](https://pepvault.app/guides/cagrisema-fda-decision#source-10). They take CagriSema or placebo, stepped up every 4 weeks over 16 weeks, then held for 64 more; the primary endpoint, the result the trial is built to test, is the change in body weight at 80 weeks[10](https://pepvault.app/guides/cagrisema-fda-decision#source-10). Primary completion, per ClinicalTrials.gov, is March 1, 2027, an estimate and not a results date[10](https://pepvault.app/guides/cagrisema-fda-decision#source-10).

REDEFINE 11 comes after the decision, so it cannot shape the first label. It could shape the second. The number to compare it with is REDEFINE 1's: 22.7% at 68 weeks for people who stayed on treatment[5](https://pepvault.app/guides/cagrisema-fda-decision#source-5). Two larger trials follow it: REDEFINE 3, a heart outcomes trial in 7,101 people with cardiovascular disease, primary completion September 2027 per ClinicalTrials.gov[15](https://pepvault.app/guides/cagrisema-fda-decision#source-15), with results Novo expects in the second half of 2027[2](https://pepvault.app/guides/cagrisema-fda-decision#source-2), and a high-dose trial of cagrilintide 2.4 mg with semaglutide 7.2 mg, which Novo expects to read out in the first half of 2028[3](https://pepvault.app/guides/cagrisema-fda-decision#source-3) [16](https://pepvault.app/guides/cagrisema-fda-decision#source-16).

## What should you look for on decision day?

On decision day, the press release and the label answer these, in order:

- Approved or not: an approval, or a complete response letter with what is missing.
- The brand name: CagriSema is a working name, and the brand appears with the approval.
- Who it is for: the filing asked for adults with obesity, or overweight with a weight-related condition[1](https://pepvault.app/guides/cagrisema-fda-decision#source-1).
- The maintenance dose or doses: 2.4 mg/2.4 mg only, or also the 1.0 and 1.7 mg steps REDEFINE 9 tested.
- The dose schedule: how many weeks each step lasts and how the pen is used.
- The boxed warning and any amylin-specific warning.
- The list price, and when pharmacies stock it: Novo expects the US launch in early 2027[2](https://pepvault.app/guides/cagrisema-fda-decision#source-2).

<!--promo-->

PepVault logs CagriSema as one weekly shot, so the dose you took and the weight trend that follows sit on one screen for your prescriber. [Log it in PepVault](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-cagrisema-fda-decision-inline&mt=8)

<!--/promo-->

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-card-next&mt=8)

<!--/promo-->

## Sources

1. Novo Nordisk. Novo Nordisk files for FDA approval of CagriSema (company announcement). December 18, 2025. [novonordisk.com](https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916470)
2. Novo Nordisk A/S, Form 6-K: Financial report for 1 January to 30 September 2026 (company announcement No 65/2026). November 4, 2026. [sec.gov](https://www.sec.gov/Archives/edgar/data/353278/000162828026069805/caq32026.htm)
3. Novo Nordisk A/S, Form 6-K: Financial report for the first six months of 2026 (R&D update and anticipated milestones). [sec.gov](https://www.sec.gov/Archives/edgar/data/353278/000035327826000023/caq22026.htm)
4. Novo Nordisk. CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial (company announcement). February 23, 2026. [novonordisk.com](https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916501)
5. Novo Nordisk A/S, Form 6-K: CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial (company announcement No 99/2024). December 20, 2024. [sec.gov](https://www.sec.gov/Archives/edgar/data/353278/000117184324007023/f6k_122024.htm)
6. Garvey WT et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity (REDEFINE 1). N Engl J Med. 2025. [PubMed 40544433](https://pubmed.ncbi.nlm.nih.gov/40544433/)
7. Davies MJ et al. Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes (REDEFINE 2). N Engl J Med. 2025. [PubMed 40544432](https://pubmed.ncbi.nlm.nih.gov/40544432/)
8. Yamauchi et al. Co-administered cagrilintide and semaglutide versus semaglutide alone in Japan and Taiwan (REDEFINE 5). Lancet Diabetes Endocrinol. 2026. [PubMed 42009015](https://pubmed.ncbi.nlm.nih.gov/42009015/)
9. Wharton S et al. Cagrilintide-semaglutide 1.7 mg each and 1.0 mg each in adults with overweight or obesity (REDEFINE 9). Lancet Diabetes Endocrinol. 2026. [PubMed 43033821](https://pubmed.ncbi.nlm.nih.gov/43033821/)
10. ClinicalTrials.gov NCT07011667: CagriSema for weight management and long-term weight maintenance in participants with obesity (Novo Nordisk; REDEFINE 11). [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07011667)
11. ClinicalTrials.gov NCT05567796: REDEFINE 1 (Novo Nordisk). [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05567796)
12. FDA. PDUFA reauthorization performance goals and procedures, fiscal years 2023 through 2027 (PDUFA VII commitment letter), section I.A. [fda.gov](https://www.fda.gov/media/151712/download)
13. openFDA Drugs@FDA: search for products with the active ingredient cagrilintide (no matches, November 20, 2026). [api.fda.gov](https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:%22CAGRILINTIDE%22)
14. WEGOVY (semaglutide) injection and tablets prescribing information, DailyMed, June 2026. [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b)
15. ClinicalTrials.gov NCT05669755: REDEFINE 3, CagriSema cardiovascular outcomes (Novo Nordisk). [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05669755)
16. ClinicalTrials.gov NCT07564414: two doses of CagriSema and semaglutide in obesity with or without type 2 diabetes (Novo Nordisk). [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07564414)
17. ClinicalTrials.gov NCT06131437: REDEFINE 4, CagriSema 2.4 mg/2.4 mg vs tirzepatide 15 mg (Novo Nordisk). [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06131437)

<!--promo-->

Newsletter · Weekly

## The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

<!--/promo-->

## Next guide · GLP-1

Guide · GLP-1

### [MariTide phase 3 results (MARITIME-1): what to expect](https://pepvault.app/guides/maritime-1-results)

MariTide's phase 3 MARITIME-1 trial: what it tests, what phase 2 showed, the bar Zepbound and Wegovy set, and when the 72-week results are expected.

Read the next guide

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## In the library

- [CagriSema Studied range: 0.25–2.4 mg](https://pepvault.app/peptides/cagrisema)
- [Cagrilintide Studied range: 0.25–2.4 mg](https://pepvault.app/peptides/cagrilintide)
- [Semaglutide Studied range: 0.25–2.4 mg](https://pepvault.app/peptides/semaglutide)

## Related guides

- Guide · GLP-1s

  ### [The Wegovy pill: what it is, how its label differs from the shot, and the trial numbers](https://pepvault.app/guides/the-wegovy-pill)

  The Wegovy pill is daily semaglutide, FDA approved in December 2025. How to take it, its doses beside the weekly shot's, and OASIS 4 next to STEP 1.

  Read the guide
- Guide · GLP-1s

  ### [Wegovy and Ozempic dosage: both labels' steps in one table, and why the two differ](https://pepvault.app/guides/wegovy-and-ozempic-dosage)

  Wegovy and Ozempic dosage side by side: both FDA labels' four-week steps, the maintenance doses and the max, why they differ and what the trials saw per dose.

  Read the guide
- Guide · GLP-1s

  ### [Stopping a GLP-1: what happens to your weight](https://pepvault.app/guides/stopping-a-glp-1)

  What happened to weight when semaglutide and tirzepatide were stopped in STEP 1, STEP 4 and SURMOUNT-4: how much came back, how fast, and what the labels say.

  Read the guide

## Guides

- [All guides](https://pepvault.app/guides)
- [How we research](https://pepvault.app/guides/how-we-research)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this guide

### CagriSema

- [CagriSema: the full reference](https://pepvault.app/peptides/cagrisema)
- [CagriSema dose guide](https://pepvault.app/lab/dosage/cagrisema)

### Cagrilintide

- [Cagrilintide: the full reference](https://pepvault.app/peptides/cagrilintide)
- [Cagrilintide dose guide](https://pepvault.app/lab/dosage/cagrilintide)

### Mixing charts

- [Cagrilintide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/cagrilintide-5mg)
- [Cagrilintide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/cagrilintide-10mg)
- [Semaglutide 2 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-2mg)
- [Semaglutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-5mg)
- [Semaglutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-10mg)

### Studies

- [CagriSema: 30.3% hit both BMI and waist-to-height targets at 68 weeks](https://pepvault.app/research/cagrilintide-redefine-1-2026)
- [CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5](https://pepvault.app/research/cagrisema-redefine-5-2026)
- [CagriSema: HbA1c down 2.33% at 40 weeks in REIMAGINE 3](https://pepvault.app/research/cagrisema-reimagine-3-2026)
- [All 4 studies](https://pepvault.app/research#cagrisema)
- [All 7 studies](https://pepvault.app/research#cagrilintide)

### Compared with

- [CagriSema vs Semaglutide](https://pepvault.app/peptides/compare/cagrisema-vs-semaglutide)
- [CagriSema vs Tirzepatide](https://pepvault.app/peptides/compare/cagrisema-vs-tirzepatide)
- [CagriSema vs Amycretin](https://pepvault.app/peptides/compare/cagrisema-vs-amycretin)
- [Cagrilintide vs Semaglutide](https://pepvault.app/peptides/compare/cagrilintide-vs-semaglutide)
- [Retatrutide vs Cagrilintide](https://pepvault.app/peptides/compare/retatrutide-vs-cagrilintide)
- [Tirzepatide vs Cagrilintide](https://pepvault.app/peptides/compare/tirzepatide-vs-cagrilintide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)

### The GLP-1 path

- [Retatrutide week by week](https://pepvault.app/guides/retatrutide-week-by-week)
- [Retatrutide dosage: the trial step-ups](https://pepvault.app/guides/retatrutide-dosage-in-trials)
- [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)
- [Semaglutide week by week](https://pepvault.app/guides/semaglutide-week-by-week)
- [Tirzepatide dosage: every step from 2.5 to 15 mg (Mounjaro and Zepbound)](https://pepvault.app/guides/tirzepatide-dosage)
- [Wegovy and Ozempic dosage: both labels' steps in one table, and why the two differ](https://pepvault.app/guides/wegovy-and-ozempic-dosage)
- [How to use the Zepbound KwikPen](https://pepvault.app/guides/how-to-use-the-zepbound-kwikpen)
- [How to use the Ozempic and Wegovy pens: needles, the dose counter and clicks](https://pepvault.app/guides/how-to-use-ozempic-and-wegovy-pens)
- [What time of day to take your GLP-1 shot or pill, and can you change the day?](https://pepvault.app/guides/when-to-take-your-glp-1)
- [Switching GLP-1s: Ozempic to Zepbound, shot to pill, and what the trials tested](https://pepvault.app/guides/switching-between-glp-1s)
- [Ozempic vs Wegovy vs Mounjaro vs Zepbound: the four labels in one table](https://pepvault.app/guides/ozempic-wegovy-mounjaro-zepbound)
- [Is Ozempic insulin? GLP-1, GIP and insulin explained](https://pepvault.app/guides/is-ozempic-insulin)
- [The Wegovy pill: what it is, how its label differs from the shot, and the trial numbers](https://pepvault.app/guides/the-wegovy-pill)
- [Ozempic and Wegovy side effects: what the trials counted and when they showed up](https://pepvault.app/guides/ozempic-and-wegovy-side-effects)
- [Semaglutide vs tirzepatide side effects: what the head-to-head trials found](https://pepvault.app/guides/sema-vs-tirzepatide-side-effects)
- [Microdosing a GLP-1: what it means and what has been tested](https://pepvault.app/guides/microdosing-a-glp-1)
- [GLP-1s and sleep apnea: Zepbound's OSA approval](https://pepvault.app/guides/glp-1-and-sleep-apnea)
- [Retatrutide first dose: the first four weeks in the trials](https://pepvault.app/guides/retatrutide-first-dose)
- [Retatrutide side effects: what the trials counted](https://pepvault.app/guides/retatrutide-side-effects)
- [Retatrutide not working? Stalls, slow responders and the plateau](https://pepvault.app/guides/retatrutide-not-working)
- [Switching from tirzepatide to retatrutide: what is known](https://pepvault.app/guides/tirzepatide-to-retatrutide)
- [Is retatrutide safe? What the trials reported](https://pepvault.app/guides/is-retatrutide-safe)
- [When will retatrutide be approved?](https://pepvault.app/guides/when-will-retatrutide-be-approved)
- [TRIUMPH-5 results: retatrutide vs tirzepatide head to head](https://pepvault.app/guides/triumph-5-results)
- [MariTide phase 3 results (MARITIME-1): what to expect](https://pepvault.app/guides/maritime-1-results)
- [Aleniglipron: the GLP-1 pill, and the trial switching people from shots to it](https://pepvault.app/guides/aleniglipron-switch-trial)
- [Mounjaro and Zepbound side effects by dose: the rates at each step](https://pepvault.app/guides/mounjaro-zepbound-side-effects)
- [Hair loss on a GLP-1: how common it is per drug, and why](https://pepvault.app/guides/hair-loss-on-a-glp-1)
- ["Ozempic face": what it is, and where the weight comes from](https://pepvault.app/guides/ozempic-face)
- [Foundayo (orforglipron) vs the shots: the trial numbers side by side](https://pepvault.app/guides/foundayo-vs-the-shots)
- [Is compounded semaglutide or tirzepatide the same as Ozempic or Zepbound?](https://pepvault.app/guides/compounded-glp-1-vs-brand)
- [Why compounded semaglutide and tirzepatide come with B12, glycine or B6, and what it changes](https://pepvault.app/guides/compounded-glp-1-with-b12)
- [Is there a generic Ozempic? Generic semaglutide and Sevmia](https://pepvault.app/guides/generic-semaglutide)
- [How much does a GLP-1 cost in 2026? Zepbound, Wegovy and Medicare prices](https://pepvault.app/guides/how-much-does-a-glp-1-cost)
- [What to eat on a GLP-1: what the trials and the guidelines say](https://pepvault.app/guides/what-to-eat-on-a-glp-1)
- [How much protein per day? The numbers by weight and goal](https://pepvault.app/guides/how-much-protein-per-day)
- [Muscle on a GLP-1: how much of the weight lost is lean mass?](https://pepvault.app/guides/muscle-on-a-glp-1)
- [Intermittent fasting on a GLP-1: what the trials and labels say](https://pepvault.app/guides/intermittent-fasting-on-a-glp-1)
- [Coffee on a GLP-1: can you drink it, and why it can taste different](https://pepvault.app/guides/coffee-on-a-glp-1)
- [Food noise on a GLP-1: what it is and what happens after stopping](https://pepvault.app/guides/food-noise-on-a-glp-1)
- [GLP-1s and menopause: what the trials say about women in midlife](https://pepvault.app/guides/glp-1s-and-menopause)
- [Stopping a GLP-1: what happens to your weight](https://pepvault.app/guides/stopping-a-glp-1)
- [How to keep the weight off after a GLP-1: what each trial tested](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1)
- [Berberine vs metformin vs a GLP-1: what each does to weight and glucose](https://pepvault.app/guides/berberine-vs-metformin-vs-glp-1)
- [Natural GLP-1 alternatives: what the evidence shows for berberine, fiber and supplements](https://pepvault.app/guides/natural-glp-1-alternatives)
- [What is 5-Amino-1MQ? What's been measured](https://pepvault.app/guides/5-amino-1mq-explained)
- [Retatrutide from a lab vial: what independent testing found](https://pepvault.app/guides/retatrutide-lab-vial-tests)
- [Switching from Saxenda to Wegovy: how the change works](https://pepvault.app/guides/saxenda-to-wegovy)
- [Do you stop Ozempic, Wegovy, Mounjaro or Zepbound before surgery?](https://pepvault.app/guides/glp-1-before-surgery)
- [Diarrhea on a GLP-1: how common, and how long it lasts](https://pepvault.app/guides/diarrhea-on-a-glp-1)
- [Dizziness on a GLP-1: dehydration, blood pressure or blood sugar?](https://pepvault.app/guides/dizziness-on-a-glp-1)
- [Heartburn and acid reflux on a GLP-1: the rates, the timing and what helps](https://pepvault.app/guides/heartburn-on-a-glp-1)
- [Does Ozempic or Mounjaro make you tired? Fatigue in the trials](https://pepvault.app/guides/glp-1-fatigue)
- [Can a GLP-1 cause low blood sugar if you do not have diabetes?](https://pepvault.app/guides/glp-1-low-blood-sugar)
- [Is there a medicine for GLP-1 nausea? Tradipitant, so far](https://pepvault.app/guides/tradipitant-for-glp-1-nausea)
- [GLP-1s and mood: depression, anxiety and what the FDA review found](https://pepvault.app/guides/glp-1s-and-mood)
- [Can Ozempic cause vision loss? GLP-1s and NAION, by the numbers](https://pepvault.app/guides/glp-1-and-naion)
- [Are GLP-1s safe long term? What the longest trials show](https://pepvault.app/guides/are-glp-1s-safe-long-term)
- [GLP-1s and the kidneys: what FLOW showed, and the dehydration risk](https://pepvault.app/guides/glp-1s-and-the-kidneys)
- [Can you drink alcohol on Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/alcohol-on-a-glp-1)
- [Do GLP-1s reduce alcohol cravings? What the trials found](https://pepvault.app/guides/glp-1-and-alcohol-cravings)
- [GLP-1s and fatty liver: what the trials measured](https://pepvault.app/guides/glp-1-and-fatty-liver)
- [GLP-1s after a gastric sleeve or bypass: regain, dosing and sleeve vs GLP-1](https://pepvault.app/guides/glp-1-after-bariatric-surgery)
- [Can you drink alcohol on retatrutide?](https://pepvault.app/guides/retatrutide-and-alcohol)
- [Ozempic, Wegovy, Mounjaro or Zepbound not working? Slow responders and plateaus in the trials](https://pepvault.app/guides/glp-1-not-working)
- [Intermittent fasting for weight and fat loss: what the trials measured](https://pepvault.app/guides/intermittent-fasting-weight-loss)
- [Can you take metformin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/metformin-with-a-glp-1)
- [GLP-1s and pregnancy: Ozempic, Wegovy, Mounjaro and Zepbound before and during](https://pepvault.app/guides/glp-1s-and-pregnancy)
- [Can you take Ozempic, Mounjaro or another GLP-1 while breastfeeding?](https://pepvault.app/guides/glp-1-while-breastfeeding)
- [Eloralintide, petrelintide and amycretin: the amylin drugs in trials](https://pepvault.app/guides/amylin-drugs-in-trials)
- [Olatorepatide (HS-20094): Regeneron's obesity drug, what is known so far](https://pepvault.app/guides/olatorepatide-explained)
- [Cagrilintide and CagriSema: what amylin adds to semaglutide](https://pepvault.app/guides/cagrilintide-and-cagrisema)
- [Berobenatide (PF-08653944, MET-097i): Pfizer's monthly GLP-1 shot, what is known so far](https://pepvault.app/guides/berobenatide-explained)
- [The GLP-1 pipeline: every drug in phase 2 and 3, and when its trials finish](https://pepvault.app/guides/glp-1-pipeline)
- [Is there a monthly GLP-1 shot? MariTide and berobenatide](https://pepvault.app/guides/monthly-glp-1-shots)
- [Cagrilintide alone: RENEW 1 phase 3 results and what to expect](https://pepvault.app/guides/renew-1-cagrilintide-results)
- [Wegovy HD: is 7.2 mg worth it, and what changes from 2.4 mg](https://pepvault.app/guides/wegovy-hd-7-2-mg)
- [Zenagamtide (amycretin): Novo's GLP-1 and amylin shot and pill, what the trials show](https://pepvault.app/guides/zenagamtide-amycretin)
- [Wegovy and Ozempic price, Medicare and WADA: what changes on January 1, 2027](https://pepvault.app/guides/glp-1-changes-january-2027)
- [Can you take sermorelin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/sermorelin-with-a-glp-1)
- [Retatrutide in women: what the studies included](https://pepvault.app/guides/retatrutide-in-women)
- [Peptides for women: what the trials in women show, and after 40](https://pepvault.app/guides/peptides-for-women)
- [Low-dose naltrexone (LDN) for weight loss: what the trials measured](https://pepvault.app/guides/ldn-for-weight-loss)
- [GLP-1s and PCOS: what the trials show, and how they compare with metformin](https://pepvault.app/guides/glp-1-and-pcos)
- [GLP-1s and sleep: insomnia, vivid dreams and the sleep apnea approval](https://pepvault.app/guides/glp-1s-and-sleep)

### Terms on this page

- [Maintenance dose](https://pepvault.app/glossary/maintenance-dose)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [Placebo](https://pepvault.app/glossary/placebo)
- [FDA approval](https://pepvault.app/glossary/fda-approval)
- [New drug application (NDA)](https://pepvault.app/glossary/nda)
- [Boxed warning](https://pepvault.app/glossary/boxed-warning)
- [Primary endpoint](https://pepvault.app/glossary/primary-endpoint)
- [Amylin analogue](https://pepvault.app/glossary/amylin-analogue)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
